Hologic, Inc. (NASDAQ:HOLX) – Equities researchers at William Blair dropped their FY2017 earnings per share (EPS) estimates for Hologic in a research report issued to clients and investors on Thursday. William Blair analyst B. Weinstein now forecasts that the medical equipment provider will post earnings per share of $2.01 for the year, down from their previous forecast of $2.02.

A number of other brokerages have also recently commented on HOLX. Stifel Nicolaus upped their price target on shares of Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, May 11th. Jefferies Group LLC restated a “buy” rating and set a $49.00 price target on shares of Hologic in a research note on Wednesday, June 28th. Bank of America Corporation restated a “neutral” rating and set a $48.00 price target (up from $44.00) on shares of Hologic in a research note on Friday, July 21st. Canaccord Genuity restated a “buy” rating and set a $53.00 price target on shares of Hologic in a research note on Tuesday, May 9th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $51.00 price target on shares of Hologic in a research note on Friday, July 14th. Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Hologic has an average rating of “Buy” and a consensus target price of $48.64.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/07/hologic-inc-holx-expected-to-earn-fy2017-earnings-of-2-01-per-share.html.

Hologic (NASDAQ HOLX) opened at 39.25 on Monday. The company has a market capitalization of $11.01 billion, a PE ratio of 14.62 and a beta of 0.90. The stock’s 50 day moving average is $45.06 and its 200 day moving average is $42.98. Hologic has a one year low of $35.15 and a one year high of $46.80.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. During the same period last year, the firm earned $0.51 earnings per share. The business’s revenue for the quarter was up 12.4% on a year-over-year basis.

In other news, VP Karleen Marie Oberton sold 4,704 shares of the stock in a transaction on Monday, July 17th. The shares were sold at an average price of $45.19, for a total value of $212,573.76. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Peter J. Valenti III sold 10,005 shares of the stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $43.44, for a total transaction of $434,617.20. Following the completion of the transaction, the insider now directly owns 20,994 shares in the company, valued at approximately $911,979.36. The disclosure for this sale can be found here. Insiders have sold a total of 63,562 shares of company stock worth $2,802,013 in the last ninety days. 0.79% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of HOLX. TrimTabs Asset Management LLC raised its position in shares of Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock worth $127,000 after buying an additional 1,408 shares during the last quarter. Advisor Partners LLC bought a new position in shares of Hologic during the first quarter worth approximately $201,000. Miles Capital Inc. bought a new position in shares of Hologic during the first quarter worth approximately $206,000. Beck Mack & Oliver LLC bought a new position in shares of Hologic during the second quarter worth approximately $209,000. Finally, Stratos Wealth Partners LTD. bought a new position in shares of Hologic during the first quarter worth approximately $210,000. 94.46% of the stock is currently owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.